Internal jugular vein hemangioma

Mirea, Daniel; Popescu, Gabriela; Stănciulescu, Răducu; Mitran, Loredana; Stanciulescu, Razvan; Dima, Stefanita; Ungureanu, Raluca; Mirea, Liliana

doi:10.26416/orl.35.2.2017.796

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the miRNA-based mortality risk score formula, we assigned a risk score to all patients and assessed the survival benefit in high (>0) vs low (<0) risk strata based on the treatment received. Compared to S only, S+ND significantly increased the median time-torecurrence from 26 months to >60 months and the 5-year survival rate from 46% to 75% (p<0.001) for the high-risk group, consistent with other reports that S+ND is associated with survival benefit in early-stage OSCC [20,21]. Improved 5-year survival in the S+ND group was most likely secondary to prolonged time-to-recurrence.…”

Section: Discussionsupporting

confidence: 88%

MicroRNA-based cancer mortality risk scoring system and hTERT expression linked with risk-adjusted treatment strategy in early-stage oral squamous cell carcinoma

Yoon

Santella

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

We have developed and validated a novel microRNA (miRNA)-based prognostic model to predict survival outcome in oral squamous cell carcinoma (OSCC) patients who are already categorized into early-stage by the TNM system. A total of 836 early-stage OSCC patients were assigned the mortality risk scores. We evaluated the efficacy of various treatment regimens in terms of survival benefit compared to surgery only in patients stratified into high and low mortality risk categories. Within the high-risk group, surgery with neck dissection significantly improved the 5-year survival to 75% from 46% (p<0.001) with surgery only. A Cox proportional hazard model on time-to-death suggests a hazard ratio of 0.37 comparing surgery with neck dissection to surgery only (95% CI: 0.2-0.6; p=0.0005). For the low-risk group, surgery only without neck dissection is the most beneficial treatment modality, as opposed to the high-risk group, in which surgery with neck dissection significantly improves 5-year survival. Regardless of treatment selected, those with risk score >1 may benefit from additional therapy to prevent cancer relapse. Based on functional analysis of the prognostic miRNAs, we identified hTERT (human telomerase reverse transcriptase) as a promising drug target to prevent cancer relapse, thereby improving cancer-free survival. We also established a functional platform for patient-derived organoid-based drug testing in an effort to link prognostic marker-based mortality risk assessment with appropriate risk-adjusted therapy to improve overall survival.

show abstract

Section: Discussionsupporting

confidence: 88%